Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid malignancies has proven more challenging than for B-cell malignancies. This is attributed to a shortage of leukemia-specific cell-surface antigens that...

Descripción completa

Detalles Bibliográficos
Autores principales: Branella, Gianna M., Lee, Jasmine Y., Okalova, Jennifer, Parwani, Kiran K., Alexander, Jordan S., Arthuzo, Raquel F., Fedanov, Andrew, Yu, Bing, McCarty, David, Brown, Harrison C., Chandrakasan, Shanmuganathan, Petrich, Brian G., Doering, Christopher B., Spencer, H. Trent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679681/
https://www.ncbi.nlm.nih.gov/pubmed/38022523
http://dx.doi.org/10.3389/fimmu.2023.1294555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679681/
https://www.ncbi.nlm.nih.gov/pubmed/38022523
http://dx.doi.org/10.3389/fimmu.2023.1294555

Ejemplares similares